Menu Search

Company Announcements

Latest announcements

Date and timeCompanyHeadlineSource
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual MeetingPR Newswire
Edgewater Wireless Announces Completion of Eleventh and Twelfth Payments of Debenture InterestBusiness Wire
Linux Foundation Welcomes Mitsubishi Electric as Gold Member During Open Source Summit JapanPR Newswire
Sustainability Focus Session 2025Business Wire
Matthews International Provides Update on Actions to Create Shareholder Value and Addresses Director NominationsPR Newswire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell MalignanciesBusiness Wire
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in ChinaGlobeNewswire
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025GlobeNewswire
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL AmyloidosisGlobeNewswire
Gartner Announces Gartner Finance Symposium/Xpo 2026 in SydneyBusiness Wire
Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)PR Newswire
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and ExpositionGlobeNewswire
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline TreatmentGlobeNewswire
Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025GlobeNewswire
Prologis announces redemption of 3.00% Notes due 2026PR Newswire
RNS announcements are delayed by up to an hour.
...